In recent decades, the emphasis of biomarker research has centered around blood-based markers.
Wet AMD biotech stock soars over 200% as lead asset matches Regeneron’s Eylea in PhII test
EyePoint Pharmaceuticals’ wet age-related macular degeneration (AMD) therapy has demonstrated non-inferiority to Regeneron’s Eylea, even with a less frequent dosing regimen in a mid-stage study,